Natera raised its 2026 revenue guidance after Q1 results showed a sharp acceleration across oncology and women’s health testing. The company increased full-year guidance to $2.74 billion to $2.82 billion, citing strong adoption of its clinical minimal residual disease (MRD) workflows and new Fetal Focus uptake. Management said women’s health unit volumes grew quarter over quarter, while oncology test volumes rose as well. Natera highlighted an expected annual run rate of 1 million MRD tests and pointed to integration with Flatiron Health OncoEMR as a driver of clinical use. The company also discussed reimbursement and pricing, including a step-up in the average selling price for Signatera in the quarter.